MedTrace Logo

Role of IL 12 and IL 23 as Potential Biomarkers in Diagnosis of Early Crohn's Disease

NCT06844565 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2025-02-25

No results posted yet for this study

Summary

This study aims to evaluate the role of Interleukin (IL)-12 and IL-23 as potential biomarkers in the diagnosis of early Crohn's disease.

Conditions

  • Interleukin 12
  • Interleukin 23
  • Biomarker
  • Diagnosis
  • Crohn Disease

Interventions

PROCEDURE

Immunohistochemistry procedure

Briefly, all slides will be rehydrated, and antigen retrieval will be performed using sodium citrate (pH = 6.0) in a pressure cooker (EDTA buffer, pH = 8.4). All slides will be blocked with endogenous peroxidase with 3% hydrogen peroxide and blocked non-specific protein with 2.5% bovine serum albumin in phosphate-buffered saline. If the result shows non-specific ileitis, immunohistochemical staining for IL-12 and IL-23 will be performed using sandwich enzyme-linked immunosorbent assays (ELISA).

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06844565 on ClinicalTrials.gov